- Home
- POLA vs AIM Comparison
POLA vs AIM Comparison
Compare POLA & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- AIM
- Stock Information
- Founded
- POLA 1979
- AIM 1966
- Country
- POLA United States
- AIM United States
- Employees
- POLA N/A
- AIM N/A
- Industry
- POLA Industrial Machinery/Components
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- POLA Miscellaneous
- AIM Health Care
- Exchange
- POLA Nasdaq
- AIM Nasdaq
- Market Cap
- POLA 8.3M
- AIM 8.8M
- IPO Year
- POLA 2016
- AIM N/A
- Fundamental
- Price
- POLA $2.09
- AIM $0.12
- Analyst Decision
- POLA
- AIM Strong Buy
- Analyst Count
- POLA 0
- AIM 2
- Target Price
- POLA N/A
- AIM $2.75
- AVG Volume (30 Days)
- POLA 63.9K
- AIM 476.8K
- Earning Date
- POLA 05-14-2025
- AIM 03-27-2025
- Dividend Yield
- POLA N/A
- AIM N/A
- EPS Growth
- POLA N/A
- AIM N/A
- EPS
- POLA N/A
- AIM N/A
- Revenue
- POLA $13,970,000.00
- AIM $170,000.00
- Revenue This Year
- POLA N/A
- AIM N/A
- Revenue Next Year
- POLA N/A
- AIM $1,693.10
- P/E Ratio
- POLA N/A
- AIM N/A
- Revenue Growth
- POLA N/A
- AIM N/A
- 52 Week Low
- POLA $1.78
- AIM $0.11
- 52 Week High
- POLA $4.90
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- POLA 31.27
- AIM 42.13
- Support Level
- POLA $2.30
- AIM $0.11
- Resistance Level
- POLA $2.54
- AIM $0.16
- Average True Range (ATR)
- POLA 0.17
- AIM 0.01
- MACD
- POLA -0.04
- AIM 0.00
- Stochastic Oscillator
- POLA 0.00
- AIM 5.00
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications primarily in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, Back-up DC generators, hybrid power systems, Li-Ion battery systems, and Marine DC generators. The Companie's geographical presence is in the United States, Canada, Mexico, South Pacific Islands, Japan, Europe and Middle East and Other Asia Pacific countries.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.